InventisBio (SH:688382)2025-02-25 07:50Financial Performance - In 2024, the company expects total operating revenue of RMB 169.10 million, a decrease of 8.85% compared to RMB 185.53 million in the previous year[4] - The net profit attributable to the parent company is projected to be RMB -245.62 million, a reduction in loss of 13.51% year-on-year from RMB -283.98 million[5] - The company reported a basic earnings per share of RMB -0.43, improving from RMB -0.49 in the previous year[4] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be RMB -255.49 million, a reduction in loss of 13.00% year-on-year[10] Asset and Equity Changes - Total assets decreased by 11.28% from RMB 2,162.27 million at the beginning of the period to RMB 1,918.36 million at the end of the period[6] - The company's equity attributable to the parent company decreased by 9.46% from RMB 1,997.60 million to RMB 1,808.62 million[6] Research and Development - The company maintained a high level of R&D investment, focusing on key clinical trials for multiple products, including D-1553 and D-0502[8] - The clinical trial for D-2570 targeting psoriasis completed Phase II with positive results in November 2024[7] - The company is advancing several products in critical registration Phase III and Phase II clinical stages[8] - The company emphasizes the importance of ongoing R&D despite current financial losses, indicating a strategic focus on long-term growth[10]